Semaglutide: the peptide behind Wegovy's weight-loss effect

What kind of peptide semaglutide actually is, and why the label matters

Peptides are molecules made of amino acid chains, shorter than full proteins and highly specific in what they bind to. Semaglutide is a 31-amino-acid peptide analogue of GLP-1, meaning it was built to look enough like the natural hormone to activate the same receptor, but with deliberate structural changes that make it far more durable in the body. Natural GLP-1 breaks down within minutes. Semaglutide's half-life is roughly a week, which is why a single weekly dose is enough to maintain consistent receptor activity.

That receptor, the GLP-1 receptor, sits on cells across the gut, pancreas and brain. When semaglutide binds it, three things happen that matter for weight management: the pancreas releases more insulin in response to food, glucagon secretion drops, and the brain receives stronger satiety signals. Gastric emptying also slows, so meals feel more substantial for longer. The NHS medicines page on semaglutide describes this mechanism in plain terms and is a reliable first reference if you want to read further.

Because of its peptide structure, semaglutide cannot survive digestion in the standard way a small-molecule drug might, which is why the injection form (Wegovy) dominated for years. If you want a fuller grounding in how these molecules work, our guide to semaglutide peptides covers the science in more detail. The oral Wegovy tablet pairs semaglutide with an absorption enhancer called SNAC to get enough of the peptide across the stomach lining. It is a meaningful engineering solution, not a minor reformulation.

Why semaglutide is prescribed rather than available freely, what the peptide classification means in practice

This is the decision point that surprises some people who find semaglutide marketed online in different forms. In the UK, the licensed Wegovy formulation is a Prescription-Only Medicine (POM), which means it can only be legally supplied following a clinical assessment by a qualified prescriber. That requirement exists because the peptide has real physiological effects (on insulin, on gastric function, on heart rate) and because the dose titration schedule needs professional oversight to manage side effects and confirm it is working.

Peptide preparations labelled as semaglutide and sold without a prescription (sometimes marketed as research peptides or compounded alternatives) are not the same product. The MHRA has been explicit that unregulated semaglutide preparations fall outside the licensed supply chain and carry genuine safety risks. If you are weighing up where to access treatment, our weight-loss treatment consultation page sets out the regulated route clearly.

It is also worth understanding that not all semaglutide brands carry the same licence. Ozempic contains semaglutide but is licensed for type 2 diabetes, not weight management. Wegovy, at higher doses and with its own clinical evidence base, holds the weight-management licence. Presenting one as a substitute for the other is clinically and legally incorrect, something a prescriber will always clarify.

How the semaglutide peptide compares with tirzepatide, the factor that shapes the clinical choice

People researching semaglutide as a peptide often find themselves comparing it with tirzepatide (Mounjaro), which works differently at the molecular level. Tirzepatide is a dual agonist, it activates both the GLP-1 receptor and the GIP receptor simultaneously. Semaglutide targets GLP-1 alone.

In the SURMOUNT-5 head-to-head trial published in 2025, tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks in adults with obesity and no diabetes. That data is cited in the NICE technology appraisal for tirzepatide (TA1026), which notes the indirect comparison favours tirzepatide. The newer 7.2 mg semaglutide dose narrows that gap in trials, reporting roughly 20.7% average loss at 72 weeks, approaching tirzepatide's results at its highest maintenance dose.

Neither molecule is universally superior; the right choice depends on someone's medical history, how they tolerated earlier doses, whether they prefer injections or tablets, and what their prescriber recommends after reviewing the whole picture. You can read more about how the semaglutide peptide performs for weight loss or explore the question of whether Wegovy counts as a peptide treatment in more detail. For a broader overview of the Wegovy product itself, the Wegovy information page covers the licensed indications, dose schedule and evidence.

Getting a semaglutide prescription through a regulated UK pharmacy

The practical question is usually: how do I access this properly? In the UK, the route is a prescription from a qualified prescriber, either via an NHS specialist weight management service (subject to eligibility criteria and, commonly, significant waiting times) or through a GPhC-registered private pharmacy following an online or in-person consultation.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally the same day, a real clinician reviews your answers, not software. If treatment is clinically suitable and you order before 12pm on a weekday, it is dispatched the same day and arrives free the next working day via tracked DPD delivery, in plain packaging. Orders placed later in the week go out the next working day; if you time it around a bank holiday or a Friday payday, it is worth knowing the cutoff falls on the working day before. You can verify our pharmacy on the GPhC register (registration 9012878).

If you want to understand more about how semaglutide dosing is structured, or read the prescribing detail in the semaglutide SPC, those resources go deeper on the clinical specifics. Our about page covers how the service is structured. When you are ready to find out whether semaglutide is suitable for you, start your free consultation, there is no obligation and no charge for the clinical assessment itself.